In an early-stage trial of 61 patients with metastatic pancreatic cancer, tumors shrank or disappeared in 60.7% who received daraxonrasib with chemotherapy.
At 32 mg, ERAS-0015 shrank tumors in 11 of 25 pancreatic cancer patients and three of five lung cancer patients in early trial results reported by Medical Xpress.
Reported by 3 outlets
This Week in Medicine
The week in medicine, in five minutes
The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.